Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) CFO Scott A. Holmes sold 2,582 shares of Keryx Biopharmaceuticals stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $6.03, for a total value of $15,569.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Keryx Biopharmaceuticals, Inc. (KERX) opened at 6.48 on Wednesday. The stock’s market capitalization is $769.50 million. Keryx Biopharmaceuticals, Inc. has a 12-month low of $4.11 and a 12-month high of $8.38. The stock has a 50 day moving average price of $6.87 and a 200 day moving average price of $6.79.

ILLEGAL ACTIVITY WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://theolympiareport.com/2017/11/01/keryx-biopharmaceuticals-inc-kerx-cfo-scott-a-holmes-sells-2582-shares.html.

A number of large investors have recently bought and sold shares of KERX. Wells Fargo & Company MN grew its stake in Keryx Biopharmaceuticals by 21.3% in the first quarter. Wells Fargo & Company MN now owns 73,926 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 12,987 shares in the last quarter. Parametric Portfolio Associates LLC lifted its holdings in Keryx Biopharmaceuticals by 60.1% in the first quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock worth $1,189,000 after acquiring an additional 72,436 shares during the last quarter. Stifel Financial Corp lifted its holdings in Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 3,478 shares during the last quarter. American International Group Inc. lifted its holdings in Keryx Biopharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 48,622 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 3,220 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Keryx Biopharmaceuticals by 1.2% in the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 300 shares during the last quarter. Institutional investors and hedge funds own 65.20% of the company’s stock.

A number of analysts have issued reports on the company. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Maxim Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Keryx Biopharmaceuticals in a report on Thursday, July 20th. ValuEngine downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Finally, Zacks Investment Research downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $7.48.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.